Micropol extends contract with Biotage

The Swedish and British medtech global Biotage has extended and increased its current contract with Micropol. The contract, which was first signed in 2017, will secure deliveries to Biotage’s UK operations until the second quarter of 2024.

Micropol extends contract with Biotage

Micropol successfully collaborate with our Research & Development team in Uppsala and are one of our key strategic suppliers working effectively with us for an improved and efficient supply chain. We are very pleased with the quality and service Micropol provides”, says Michelle Parton, Senior Strategic Buyer at Biotage.

At Micropol, we acknowledge that quality and reliability are crucial for patient safety. We have built our reputation as a technology leader in the area of passive fiber optics much due to our engineering expertise. In the medtech customer segment, our long history of customer application engineering is used by customers whom are operational in everything from liquid detection, to minimal invasive surgery.



About Biotage: The history of Biotage goes back to the late 1960’s when the foundation of its success was built by rationalize the customer’s workflow and reduce their impact on the environment, for example by using a lower volume of solvents. Today, Biotage is a global company dedicated to developing high quality products for advancement in Life Science with innovative solutions for separation within organic and analytical chemistry. The company is headquartered in Uppsala, Sweden and has offices in the US, UK, China, Korea, India and Japan.

Strengthening the team with new key colleagues

21 October 2025

Micropol Fiberoptic is growing rapidly, driven by an increased global demand for fiber optic solutions. To meet this expansion, we are investing in both our production capacity and our people. As a result, several new talent colleagues have joined Micropol in recent weeks.